Document Detail


Esthesioneuroblastoma: prognosis and management.
MedLine Citation:
PMID:  8492845     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Forty-nine patients with esthesioneuroblastoma were treated at the Mayo Clinic between 1951 and 1990. Their clinical manifestations and treatment results were reviewed to identify possible prognostic factors. The 5-year survival rate for all patients was 69%. Tumor progression occurred in 25 patients (51%; no local control in 6 and local recurrence in 19). Metastasis was found in 15 patients (31%; regional in 10 and distant in 9). Nineteen patients died directly from metastatic or intracranial tumor extension. The pathological grade of the tumor was the most significant prognostic factor identified. The 5-year survival rate was 80% for the low-grade tumors and 40% for the high-grade tumors (P = 0.0001). Surgical treatment alone is effective for low-grade tumors if tumor-free margins can be obtained. Radiation is used for low-grade tumors when margins are close, for residual or recurrent disease, and for all high-grade cancers. The poor prognosis associated with high-grade tumors may also mandate the addition of chemotherapy. Recurrent tumor and regional metastasis should be treated aggressively because this approach has been shown to be worthwhile. A craniofacial resection is now the surgical procedure performed in all cases. Because recurrence can occur after 5 or even 10 years, long-term follow-up is mandatory.
Authors:
A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Related Documents :
16098355 - Urothelial carcinoma of the upper urinary tract: comparison between the who/isup 1998 c...
10884805 - Neuroendocrine carcinomas (carcinoid tumor) of the thymus. a clinicopathologic analysis...
15338305 - Expression of annexin ii in conventional renal cell carcinoma is correlated with fuhrma...
9192545 - P53 in biopsies of oral squamous cell carcinoma. a comparative study with a malignancy ...
471845 - Nasal skin cancer:hazard to a uniquely exposed structure.
9728615 - Thrombomodulin expression in transitional cell carcinoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurosurgery     Volume:  32     ISSN:  0148-396X     ISO Abbreviation:  Neurosurgery     Publication Date:  1993 May 
Date Detail:
Created Date:  1993-06-17     Completed Date:  1993-06-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7802914     Medline TA:  Neurosurgery     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  706-14; discussion 714-5     Citation Subset:  IM    
Affiliation:
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Brain / pathology
Brain Neoplasms / drug therapy,  pathology,  radiotherapy,  surgery*
Chemotherapy, Adjuvant
Child
Child, Preschool
Combined Modality Therapy
Cranial Irradiation
Craniotomy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy,  pathology,  radiotherapy,  surgery
Neoplasm Staging
Neuroectodermal Tumors, Primitive, Peripheral / drug therapy,  pathology,  radiotherapy,  surgery*
Nose / pathology
Nose Neoplasms / drug therapy,  pathology,  radiotherapy,  surgery*
Prognosis
Radiotherapy Dosage

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stereotactic radiosurgery of cavernous sinus meningiomas as an addition or alternative to microsurge...
Next Document:  Primary leptomeningeal melanoma: an unusually aggressive tumor in childhood.